Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucémie Aiquë Myéloïde Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4377-4385

  Aladjidi, Nathalie ^a   Auvrignon, Anne ^a   Leblanc, Thierry ^a   Perel, Yves ^a   Bénard, Antoine ^a   Bordigoni, Pierre ^a   Gandemer, Virginie ^a   Thuret, Isabelle ^a   Dalle, Jean Hugues ^a   Piguet, Christophe ^a   Pautard, Brigitte ^a   Baruchel, André ^a   Leverger, Guy ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FRANCE; HEMATOLOGY; HLA SYSTEM; HUMAN; IMMUNOLOGY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PEDIATRICS; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; ACUTE DISEASE; ADOLESCENT; ALLOTRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; INFANT; MALE; MYELOID LEUKEMIA; PRESCHOOL CHILD; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0642337947     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.066     Document Type: Article

References (31)

1. Wells RJ, Woods WG, Buckley JD, et al: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Children's Cancer Group Study. J Clin Oncol 12:2367-2377, 1994
2. Behar C, Suciu S, Benoit Y, et al: Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognosis factors: Results of the EORTC Children Leukemia Cooperative Study 58872. Med Pediatr Oncol 26:173-179, 1996
3. Michel G, Baruchel A, Tabone MD, et al: Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloblastic leukemia in first complete remission: A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 17:191-196, 1996
4. Ravindranath Y, Yaeger AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group. N Engl J Med 334:1428-1434, 1996
5. th AML trial (MRC AML 10)-Adult and Childhood Leukemia Working Parties of the Medical Research Council. Br J Haematol 101:130-140, 1998
6. Creutzig U, Ritter J, Zimmermann M, et al: Improved treatment results in high-risk pediatric acute myeloid leukemia after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin- Frankfurt-Münster 93. J Clin Oncol 19:2705-2713, 2001
7. Woods WG, Neudorf S, Gold S, et al: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 97:56-62, 2001
8. Perel Y, Auvrignon A, Leblanc T, et al: Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: Results of a prospective randomized trial, LAME 89/91-Leucámie Aiquë Myéloïde Enfant. J Clin Oncol 20:2774-2782, 2002
9. Webb DK: Management of relapsed acute myeloid leukemia. Br J Haematol 106:851-859, 1999
10. Webb KH, Wheatley K, Harrison G, et al: Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML 10 Trial. Leukemia 13:25-31, 1999
11. Stahnke K, Boos J, Bender-Götze C, et al: Duration of first remission predicts remission rates and long term survival in children with relapsed acute myelogenous leukemia. Leukemia 12:1534-1538, 1998
12. Shearer P, Katz J, Bozeman P, et al: Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia. Cancer 74:1953-1958, 1994
13. Mertens AC, Yasui Y, Neglia JP, et al: Late mortality experience in five-year survivors of childhood adolescent after cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19:3161-3162, 2001
14. Michel G, Socie G, Gebhard F, et al: Late effects of allogeneic bone marrow transplantation for children with acute leukemia in first complete remission: Impact of conditioning regimen without total-body irradiation-Report from the Societe Française de Greffe de Moelle. J Clin Oncol 15:2238-2246, 1997
15. Ginsberg JP, Lange BJ: Isolated extramedullary relapse in AML: A retrospective analysis. J Pediatr Hematol Oncol 20:389, 1998 (abstr)
16. Raimondi SC, Chang MN, Ravindranath Y, et al: Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821. Blood 94:3707-3716, 1999
17. Webb DK, Harrison G, Stevens RF, et al: Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98:1714-1720, 2001
18. Wells RJ, Woods WJ, Lampkin BC, et al: Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: A report from the Children's Cancer Group. J Clin Oncol 11:538-545, 1993
19. Hu XF, Slater A, Kantharidis P, et al: Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93:4086-4095, 1999
20. Fleischhack G, Hasan C, Graf N, et al: IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experience of a phase II trial. Br J Haematol 102:647-655, 1998
21. McCarthy AJ, Pitcher LA, Hann IM, et al: FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol 32:411-415, 1999
22. Yalman N, Sarper N, Devecioglu O, et al: Rudarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 42:198-204, 2000
23. Luczynski W, Muszynska-Roslan K, Kravczuk-Rybak M, et al: Results of IDA-FLAG program in the treatment of recurrent acute myeloblastic leukemia: Preliminary report. Med Sci Monit 7:125-129, 2001
24. Cortes J, Estey E, O'Brien S, et al: High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92:7-14, 2001
25. Michallet M, Tanguy ML, Socié G, et al: Second allogeneic hematopoietic stem cell transplantation in relapsed acute and chronic leukemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Société Française de Greffe de Moelle. Br J Haematol 108:400-407, 2000
26. Hsieh MH, Korngold AR: Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 96:1047-1055, 2000
27. Vignetti M, Rondelli R, Locatelli F, et al: Autologous bone marrow transplantation in children with acute myeloid leukemia: Report from the Italian National Pediatric Registry (AIEOP-BMT). Bone Marrow Transplant 18:59-62, 1996 (suppl 2)
28. Miller CB, Rowlings PA, Zhang MJ, et al: The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 29:1336-1346, 2001
29. Dahl GV, Lacayo NJ, Brophy N, et al: Mitoxantrone, etoposide and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 18:1867-1875, 2000
30. Sievers EL, Lange BJ, Sondel PM, et al: Children's Cancer Group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 6:S39-S44, 2000 (suppl 1)
31. Larson RA: Current use and future development of gemtuzumab ozogamicin. Semin Hematol 38:24-31, 2001